

## ASX Announcement

### BCAL Diagnostics Launch of BREASTEST *plus*™ Investor Webinar

**Sydney, Australia – 31 March 2025** – BCAL Diagnostics Limited (ASX: BDX) wishes to advise that it will host an analyst and investor webinar to discuss the launch of BREASTEST *plus*™ on Wednesday 2 April at 12:00pm AEDT.

BCAL Diagnostics CEO, Shane Ryan will be joined by Dr David Speakman, Specialist Breast Surgeon and Head of BCAL's Clinical Advisory Board.

### Webinar Registration

Please use the following link to register for the webinar:

Webinar Registration Link:

<https://s1.c-conf.com/diamondpass/10046419-pk3wc6.html>

This announcement has been approved for release by the Executive Chair of BCAL Diagnostics Limited.

## ENDS

### For further information:

**Jayne Shaw**  
Executive Chair  
Jshaw@bcaldiagnostics.com

**Shane Ryan**  
Chief Executive Officer  
Sryan@bcaldiagnostics.com

**Investor & Media Enquiries**  
Tanya Thomas  
Director Investor Relations &  
Communications  
Tthomas@bcaldiagnostics.com

### About BREASTEST *plus*™

BREASTEST *plus*™ is the first product in BCAL's BREASTEST® range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*™ is a first in class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST *plus*™ is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

### About BCAL Diagnostics

BCAL Diagnostics is an Australian and US-based biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST® range of products is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces unnecessary follow-ups and enables timely intervention resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact [info@bcaldiagnostics.com](mailto:info@bcaldiagnostics.com).